HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, announced today that it has reached an ...
HERCULES, Calif., July 31, 2025--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the ...
The market didn't react positively to the diagnostics specialist's third-quarter earnings report. It beat on both the top and bottom lines, but growth rates were low. 10 stocks we like better than Bio ...
Bio-Rad has been challenged by tough end-market conditions in life sciences tools, but the outlook for 2025 is better. The company's cautious approach has led to lackluster sales growth and margin ...
Hosted on MSN
Bio-Rad set to acquire Stilla Technologies
HERCULES, Calif. - Bio-Rad Laboratories (NYSE:BIO), Inc. (NYSE: BIO and BIO.B), a $8.49 billion market cap company known for its life science research and clinical diagnostics products, has announced ...
Bio-Rad Labs (BIO) has delivered a -8.16% change over the past year, with a 52-week range between 211.43 and 373.69. What Is the Average Daily Trading Volume of Bio-Rad Labs (BIO)? The average daily ...
ddPCR reportedly provides quantification of target molecules with unprecedented precision and sensitivity. Bio-Rad Laboratories purchased QuantaLife for $162 million in cash plus future milestone ...
HERCULES, Calif. (AP) — HERCULES, Calif. (AP) — Bio-Rad Laboratories Inc. (BIO.B) on Wednesday reported a third-quarter loss of $341.9 million, after reporting a profit in the same period a year ...
I rate Bio-Rad (BIO) with a buy rating. I start by mentioning that the low growth perspective is the negative aspect. For 2025, the company expects a 0.25% growth rate for its revenues, which might ...
Oct 26 (Reuters) - Bio-Rad Laboratories (BIO.N), opens new tab on Thursday lowered its annual revenue growth forecast, given the uncertain pace of the biopharma sector's recovery and ongoing macro ...
A federal jury Monday awarded the former general counsel of Bio-Rad Laboratories $8 million in back pay and damages — which will increase to $11 million — for whistleblower retaliation involving ...
Amortization of purchased intangible assets: we do not acquire businesses and assets on a predictable cycle. The amount of purchase price allocated to purchased intangible assets and the terms of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback